LivaNova To Buy TandemLife For Up to $250m, Adding Complementary Cardiac Surgery
London-based cardiac surgery and neuroscience group LivaNova PLC is buying privately held Pittsburgh-based TandemLife in a deal worth up to $250m. TandemLife develops advanced cardiopulmonary temporary support systems that are complementary to LivaNova's cardiac surgery segments.
You may also be interested in...
The US FDA has labelled a recall of several hundred components of the LifeSPARC circulatory support system from LivaNova as class I, the agency’s most serious recall designation.
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.
Medtech Insight recorded nine newly announced deals in February, a decline from the 17 deals recorded in January 2017 and the 12 noted in the same period last year. Nevertheless, it proved to be a busy month in the oncology and cardiovascular space, with radiotherapy specialist Varian racking up two deals in the same month to expand its cancer portfolio.